As expressed by Tan Shengcai, the Deputy Secretary General of China Chamber of Commerce of Medicines & Health Products Imports & Exports, in an interview in November 3, the year-on-year growth of gross import value of Chinese pharmaceutical products in the first three quarters of this year was 14.9%, approaching the expected growth 15% of the year and showing a positive state.
Driven by demand and policy factors in China, import of Chinese pharmaceutical products has been growing stably and rapidly; meanwhile, Chinese pharmaceutical industry’s blending in international multilateral mutual recognition system is accelerating too.
Right under this background, how Chinese enterprises will face the international pharmaceutical mutual recognition system represented by PICS (Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme), etc. has become the industry’s focus in the world. Meng Dongping, the Vice President of China Chamber of Commerce of Medicines & Health Products Imports & Exports , expressed that pharmaceutical industry of China, a great power in global pharmaceutical production and consumption, held an open mind to the above point. It would be a challenge as well as a great opportunity for China to enter international pharmaceutical multilateral mutual recognition system.
Meng Dongping said, “In our opinion, the unification of regulatory standards is conductive to the better ‘going out’ of Chinese enterprises and products. Enterprises’ fighting alone in the intensified international competitive situation will not work, and there shall be the arrangement and guarantee of system and institution.”
